Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the , taking place in Lisbon, Portugal March 5-9, 2024.
Maria Maccecchini, PhD, Founder, President, and CEO of Annovis, will join a forum discussion focused on new approaches for alpha-synuclein (αSyn), LRKK2, and GBA pathologies. Aggregated αSyn is the major constituent of Lewy bodies and a pathogenic hallmark of all synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. It is present in a number of other neurodegenerative diseases and is responsible for axonal impairment and synaptic degeneration. The panel will discuss the use of biomarkers to define PD and differentiate it from other synucleinophaties, the course, the progression, and staging of patients.
The forum will feature a line-up of international discussants including Fabrizio Stocchi, MD, PhD (University San Raffaele Roma), Gennaro Pagano, MD, MSc, PhD, eMBA (Roche), John J. Alam, MD (CervoMed, Inc.), Maria Maccecchini, PhD (Annovis Bio), Pam McLean, PhD (Mayo Clinic), Werner Poewe, MD (Medical University of Innsbruck), and Zdenek Berger, PhD (Biogen).
Session details:
Forum 03: New Insights in the Development of Biomarkers, Imaging, and Therapy of Alpha-Synuclein, LRKK2, and GBA Pathologies
Session Time: 17:30 - 18:30
Date: March 7, 2024
Room: Auditorium I
Chairs: Jamie Eberling, PhD (Michael J Fox Foundation), Walter J. Koroshetz, MD (National Institute of Neurological Disorders and Stroke)
About Annovis Bio, Inc.
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and other chronic neurodegenerative diseases. It is believed to be the only company developing a drug for both AD and PD designed to inhibit more than one neurotoxic protein to restore axonal and synaptic activity. By improving brain function, the company’s goal is to treat memory loss and dementia associated with AD as well as body and brain dysfunction associated with PD. For more information on Annovis Bio, please visit the Company's website and follow us on and .
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company advises caution in reliance on forward-looking statements. Forward-looking statements include, without limitation, the Company's plans related to clinical trials. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those implied by forward-looking statements, including regarding patient enrollment, the effectiveness of Buntanetap and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety and tolerability of buntanetap. See also additional risk factors set forth in the Company's periodic filings with the SEC, including, but not limited to, those risks and uncertainties listed in the section entitled "Risk Factors," in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC. All forward-looking statements in this press release are based on information available to the Company as of the date of this filing. The Company expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Investor Contacts:
Maria Maccecchini, Ph.D.
